- Home
- OTLK vs FSEA Comparison
OTLK vs FSEA Comparison
Compare OTLK & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- FSEA
- Stock Information
- Founded
- OTLK 2010
- FSEA 1890
- Country
- OTLK United States
- FSEA United States
- Employees
- OTLK N/A
- FSEA N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- FSEA Savings Institutions
- Sector
- OTLK Health Care
- FSEA Finance
- Exchange
- OTLK Nasdaq
- FSEA Nasdaq
- Market Cap
- OTLK 48.3M
- FSEA 53.7M
- IPO Year
- OTLK 2016
- FSEA N/A
- Fundamental
- Price
- OTLK $0.93
- FSEA $11.66
- Analyst Decision
- OTLK Buy
- FSEA
- Analyst Count
- OTLK 5
- FSEA 0
- Target Price
- OTLK $8.50
- FSEA N/A
- AVG Volume (30 Days)
- OTLK 7.8M
- FSEA 3.2K
- Earning Date
- OTLK 08-14-2025
- FSEA 11-07-2025
- Dividend Yield
- OTLK N/A
- FSEA N/A
- EPS Growth
- OTLK N/A
- FSEA N/A
- EPS
- OTLK N/A
- FSEA N/A
- Revenue
- OTLK $1,505,322.00
- FSEA $14,095,000.00
- Revenue This Year
- OTLK N/A
- FSEA N/A
- Revenue Next Year
- OTLK $484.88
- FSEA N/A
- P/E Ratio
- OTLK N/A
- FSEA N/A
- Revenue Growth
- OTLK N/A
- FSEA 30.26
- 52 Week Low
- OTLK $0.79
- FSEA $8.90
- 52 Week High
- OTLK $8.32
- FSEA $11.95
- Technical
- Relative Strength Index (RSI)
- OTLK 31.89
- FSEA 57.11
- Support Level
- OTLK $0.82
- FSEA $11.43
- Resistance Level
- OTLK $0.98
- FSEA $11.95
- Average True Range (ATR)
- OTLK 0.27
- FSEA 0.14
- MACD
- OTLK -0.15
- FSEA 0.02
- Stochastic Oscillator
- OTLK 5.25
- FSEA 51.67
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.